ESMOLOL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for esmolol hydrochloride and what is the scope of freedom to operate?

Esmolol hydrochloride is the generic ingredient in six branded drugs marketed by Baxter Hlthcare, Am Regent, Amneal, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hq Spclt Pharma, Mylan Institutional, Mylan Labs Ltd, and Sagent Pharms Inc, and is included in thirteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Esmolol hydrochloride has seven patent family members in seven countries.

There are five drug master file entries for esmolol hydrochloride. Fourteen suppliers are listed for this compound.

Summary for ESMOLOL HYDROCHLORIDE

International Patents:	7
US Patents:	2
Tradenames:	6
Applicants:	11
NDAs:	13
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	130
Patent Applications:	1,184
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESMOLOL HYDROCHLORIDE
What excipients (inactive ingredients) are in ESMOLOL HYDROCHLORIDE?	ESMOLOL HYDROCHLORIDE excipients list
DailyMed Link:	ESMOLOL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for ESMOLOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	PHASE1
John Basmaji	PHASE1
Western University, Canada	PHASE1

See all ESMOLOL HYDROCHLORIDE clinical trials

Pharmacology for ESMOLOL HYDROCHLORIDE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ESMOLOL HYDROCHLORIDE

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for ESMOLOL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BREVIBLOC IN PLASTIC CONTAINER	Injection	esmolol hydrochloride	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags	019386	1	2014-01-31

US Patents and Regulatory Information for ESMOLOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003	AP	RX	Yes	Yes
Gland	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	INJECTABLE;INJECTION	208538-001	Aug 14, 2019	AP	RX	No	No
Amneal	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	INJECTABLE;INJECTION	216603-002	Dec 13, 2022	AP	RX	No	No
Hikma	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	INJECTABLE;INJECTION	076323-001	Aug 10, 2004	AP	RX	No	No
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-006	Feb 25, 2003	AP	RX	Yes	Yes
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-001	Apr 7, 2016		RX	Yes	Yes	8,829,054		Y

Expired US Patents for ESMOLOL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-007	May 28, 2003	6,528,540*PED
Baxter Hlthcare	BREVIBLOC IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-004	Feb 16, 2001	6,310,094*PED
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-003	Aug 15, 1988	4,387,103
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-006	Feb 25, 2003	6,310,094*PED
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003	6,310,094*PED
Baxter Hlthcare	BREVIBLOC IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-004	Feb 16, 2001	4,593,119*PED

International Patents for ESMOLOL HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2948379	COMPOSITION PHARMACEUTIQUE DE COSOLVANTS PRÊTE À L'UTILISATION DANS DES RÉCIPIENTS DE MATIÈRE PLASTIQUE FLEXIBLES MODIFIÉS (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER)
World Intellectual Property Organization (WIPO)	2014143845
Canada	2906031	COMPOSITION PHARMACEUTIQUE DE COSOLVANTS PRETE A L'UTILISATION DANS DES RECIPIENTS DE MATIERE PLASTIQUE FLEXIBLES MODIFIES (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER)
South Korea	20150132835	변형된 가요성 플라스틱 용기에서 즉시 사용가능한 공용매 약학 조성물 (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER)
Australia	2014228155	Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
China	105263809	Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container

Market Dynamics and Financial Trajectory for Esmolol Hydrochloride

Last updated: January 15, 2026

Executive Summary

Esmolol hydrochloride is an ultra-short-acting beta-1 adrenergic blocker widely used in acute cardiovascular settings, notably intraoperative and postoperative management of tachycardia and hypertension. Its rapid onset and short half-life make it a preferred agent in critical care. The global market for esmolol hydrochloride is influenced by factors such as increasing prevalence of cardiac-related diseases, advancements in perioperative care, and rising adoption in intensive care units (ICUs). Despite facing competition from other beta-blockers and alternative emergent treatments, the drug's niche profile supports steady growth. This report offers a comprehensive analysis of market dynamics, forecasted financial trajectories, competitive landscape, and strategic factors shaping esmolol hydrochloride’s future.

---

Market Overview and Key Drivers

Aspect	Details
Global Market Size (2022)	Estimated at USD 300 million; projected CAGR ~6% through 2030 [1].
Major Usage Settings	Critical care, operating rooms, emergency departments.
Clinical Advantages	Rapid onset (2-10 mins), short half-life (~9 mins), precise titration.

Key Growth Drivers

1. Rising Incidence of Cardiac Conditions

   • Cardiovascular diseases (CVDs): Leading global cause of death (~17.9 million annually) [2].
   • Surgeries requiring perioperative beta-blockade increase demand.

2. Growth in Critical Care and Emergency Medicine

   • Increased ICU admissions for arrhythmias and hypertensive crises.
   • Growing preference for short-acting agents in dynamic settings.

3. Enhanced Awareness and Adoption in Protocols

   • Inclusion in guidelines such as American Heart Association (AHA) protocols.
   • Training and differentiation of critical care teams favoring esmolol's rapid titratability.

4. Regulatory and Healthcare Infrastructure Developments

   • Expanding healthcare access in emerging markets.
   • Adoption of modern critical care standards.

---

Market Challenges and Constraints

Challenges	Impacts
generic competition	Price pressures especially from low-cost generics and biosimilars.
Alternative beta-blockers	Drugs like metoprolol and atenolol with longer durations influencing formularies.
Limited brand differentiation	Clinical equivalence reduces brand loyalty.
Regulatory variations	Strict approval processes in certain regions could delay market access.

---

Competitive Landscape

Key Global Players

Company	Market Share (Estimated, 2022)	Key Strategies	Notable Products
AbbVie (Esmolol)	~45%	Brand dominance, clinical preference	Brevibloc ( brand name)
Hospira (Pfizer)	~25%	Generics, pricing strategies	Esmolol injection
Others (generic manufacturers)	~30%	Cost-effective alternatives	Various unbranded versions

Note: Brevibloc by AbbVie remains the gold standard in branding; generic manufacturers (India, China) supply cost-efficient alternatives.

Pricing Dynamics

Region	Average Price per 10 mL (USD)	Price Trends (2022–2025)
North America	$250–$350	Slight decline due to generics.
Europe	€200–€300	Stable; influence of reimbursement policies.
Asia-Pacific	$80–$150	Price-sensitive markets.

---

Financial Trajectory and Forecast

Revenue Projections (2023–2030)

Year	Estimated Global Market Revenue (USD million)	CAGR (%)	Key Assumptions
2023	320	—	Baseline, current adoption rates.
2025	400	~6%	Increased ICU utilization, expanding geographic reach.
2027	470	~4.8%	Market saturation in developed regions, rising in emerging markets.
2030	530	~3.8%	Stabilization, with innovation & competitive pressure balancing growth.

Growth Influencers

• Increase in ICU beds and critical care procedures: With ICU capacity expanding globally, demand for rapid-onset beta-blockers like esmolol is expected to rise.
• Expansion into emerging markets: Growing healthcare infrastructure and increasing urbanization stimulate demand.
• Regulatory approvals for new indications: Off-label and new clinical trial approvals could create additional revenue streams.

Revenue Breakdown by Region (2023)

Region	Percentage of Total Revenue	Key Drivers
North America	50%	High ICU prevalence, strong brand presence, regulatory reimbursement.
Europe	25%	Similar clinical adherence, aging population, enhanced critical care protocols.
Asia-Pacific	15%	Rapid healthcare development, increasing surgical procedures, affordability.
Rest of World	10%	Emerging healthcare markets with growing critical care infrastructure.

---

Strategic Factors Affecting Market Evolution

Policy & Regulatory Environment

• FDA and EMA Approvals: Continued support influences clinical use; priority given to drugs with proven safety in emergent settings.
• Pricing & Reimbursement: Reimbursement policies in the US, Europe, and Asia significantly impact profit margins.
• Biosimilar and Generic Entry: Regulatory pathways may facilitate entry; intensity of price competition intensifies.

Innovation & Formulation Developments

• Extended-release Formulations: Currently, esmolol remains primarily injection; development of alternate delivery systems could enhance market penetration.
• Combination Therapies: Synergistic protocols with other critical care agents could expand use cases.
• Digital Monitoring: Integration with ICU monitoring software offers scope for value-added applications.

---

Comparative Analysis with Similar Drugs

Parameter	Esmolol Hydrochloride	Metoprolol	Esmolol (Bioequivalent)
Onset of Action	2–10 minutes	15–30 minutes	Similar
Half-life	~9 minutes	3–4 hours	Similar
Indications	Acute tachycardia, hypertension	Chronic hypertension, angina	Similar
Formulation	IV injection	Oral, IV	IV only
Pricing	Higher (brand premium)	Lower (generic options)	Varies

---

Summary: Key Market Insights

• Dominance of branded products (e.g., Brevibloc): Maintains high market share in developed countries.
• Generics and biosimilars: Growing presence in emerging markets, exerting downward pricing pressure.
• Clinical preference: Its unique pharmacokinetics sustains niche dominance for urgent care settings.
• Market growth: Expected to expand at a CAGR of approximately 6% across the next decade, driven by increased ICU admissions and surgical procedures worldwide.
• Regulatory and reimbursement influences: Critical in shaping future adoption and pricing strategies.

---

Key Takeaways

• The esmolol hydrochloride market is poised for steady growth, underpinned by increasing global cardiovascular disease burden and expanding critical care services.
• Price competition from generics will continue to challenge margins but will be mitigated by clinical advantages and protocol preferences.
• Strategic focus on emerging markets and innovation in formulation could open additional revenue streams.
• Regulatory landscapes will heavily influence market access and competitive positioning; companies should prioritize compliance and early engagement.
• Collaboration with healthcare providers for clinical education and guideline inclusion can boost adoption rates.

---

FAQs

1. What are the primary clinical advantages of esmolol hydrochloride over other beta-blockers?
   Its rapid onset (2–10 minutes) and ultra-short half-life (~9 minutes) allow precise titration and rapid cessation, making it ideal for acute settings.

2. How does generic competition affect the market for esmolol hydrochloride?
   Generics significantly reduce prices, pressure profit margins, and challenge brand dominance, especially in cost-sensitive emerging markets.

3. What future innovations could influence the market trajectory?
   Development of extended-release formulations, combination therapies, and digital integration in monitoring could broaden applications and improve patient outcomes.

4. Which regions are expected to exhibit the highest growth for esmolol hydrochloride?
   Asia-Pacific and Latin America are anticipated to show rapid growth due to expanding healthcare infrastructure and rising surgical volumes.

5. What regulatory factors should manufacturers monitor?
   Approval pathways, reimbursement policies, and bioequivalence standards in target markets significantly influence market entry and pricing strategies.

---

References

[1] MarketsandMarkets. “Beta-Blockers Market,” 2022.
[2] World Health Organization. "Cardiovascular Diseases (CVDs)," 2021.